Brief: Alx Oncology’S Evorpacept In Combination With Zanidatamab Generates Promising, Durable Response In Patients With Advanced Her2-Positive Breast Cancer And High Cd47 Expression
07/05/2026 13:07
May 7 (Reuters) - ALX Oncology Holdings Inc ALXO.O: ALX ONCOLOGY’S EVORPACEPT IN COMBINATION WITH ZANIDATAMAB GENERATES PROMISING, DURABLE RESPONSE IN PATIENTS WITH ADVANCED HER2-POSITIVE BREAST CANCER AND HIGH CD47 EXPRESSION Source text: ID:nGNX6rkdHG Further company coverage: ALXO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ALX Oncology Holdings
See all newsALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing